Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

GSK Signs Pre-JV Vaccine Pact with Shenzhen Neptunus Interlong

publication date: Nov 21, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

GlaxoSmithKline and Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established vaccine manufacturer in China, will work together to develop flu vaccines for the China market. The two companies have signed a formal Cooperation Agreement that will lead to the formation of a JV company with $78 million of assets, if certain undisclosed conditions are met. More details...
Stock Symbol: (NYSE: GSK)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners